Assistant Professor Dr. Suteera Techakhunwut, Chulalongkorn University Faculty of Pharmacy And CEO of Phyto Farm Co, Ltd reveals the progress in the production of Chulalongkorn-Bai vaccine. prevent that COVID-19 The first generation of vaccines It is a breed from Wuhan. Those who experienced phase 1 found that side effects were no different to other vaccines Efficiency and immune stimulation similar to the AstraZeneca vaccine As for the second generation vaccine, which still uses the original strain. Phase 1 test results can give the immune system a better boost. It is similar to the mRNA type and is about to be tested in humans in Phase 2. It will start recruiting volunteers to test the vaccine in August 2023 in the 18-60 year old population, 70-100 people who have been vaccinated every time. type comes first
This test will be a booster vaccine. to see the level of immunity However, the use of the original species due to the production of the vaccine must be developed until the end of at least the 2nd stage in order to change the species If a new species is used, the process must start from the start again It is expected that the Phase 2 test results will be able to complete the test results by the end of 2023. If additional funding can be found, it will continue to test the development of the COVID vaccine in Phase 3. However, the information gained from the research will Each step is useful for vaccine and drug development. Although the situation of the cases of COVID-19 has decreased, but we have used the crisis to build knowledge in vaccine production and build a production base in the country. is to create sustainability for the country If the crisis hits again I think we can definitely produce a vaccine. In normal circumstances, we will produce other drugs and vaccines. so that we can live alone
“The goal of producing vaccines from drug leaves as a stimulant needle This will reduce part of the importation of vaccines. But the important thing is that the results of the Phase 1 test are information that can be used to produce cancer drugs,” said Assistant Professor Dr Suthira. For the operation of Bai Ya Co, Ltd, which is the first startup of Chulalongkorn University There is an industrial production capacity for vaccines. Capable of producing 5 million doses of vaccine per month or 60 million doses per year, including pharmaceutical production, it is also a research laboratory for master’s and doctoral students. Create opportunities and career paths for students in the future If possible, I would like to develop it in the next generation of new businesses. In addition, the drug company has also established a company in America. selling drugs on a global scale with production centers in Thailand, in order to create jobs in the country, including testing teams, research teams, etc.